Body fat patterning in polycystic ovary syndrome women as a predictor of the response to clomiphene

Acta Obstetricia et Gynecologica Scandinavica

Volumn 83, Issue 9, 2004, Pages 838-841

  Douchi, Tsutomu ^a   Oki, Toshimichi ^a   Yamasaki, Hideki ^a   Nakae, Mitsuhiro ^a   Imabayashi, Akiko ^a   Nagata, Yukihiro ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Body fat distribution; Clomiphene nonresponders; Clomiphene responders; Polycystic ovary syndrome

Indexed keywords

CLOMIFENE CITRATE;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY FAT; BODY HEIGHT; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; MENARCHE; OVARY POLYCYSTIC DISEASE; OVULATION; PRIORITY JOURNAL; REGRESSION ANALYSIS; STATISTICAL SIGNIFICANCE;

ADIPOSE TISSUE; ADULT; BODY COMPOSITION; BODY MASS INDEX; CLOMIPHENE; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; OBESITY; POLYCYSTIC OVARY SYNDROME; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TESTOSTERONE; TREATMENT OUTCOME;

EID: 4444351320     PISSN: 00016349     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0001-6349.2004.00369.x     Document Type: Article

References (15)

1. Bjorntorp P. The android woman - a risky condition. J Intern Med 1996; 239: 105-10.
2. Kissebach AH, Vydelingum N, Murray B, Evans DJ, Hartz AJ, Kalkhoff RK et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 1982; 54: 254-60.
3. Douchi T, Ijuin H, Nakamura S, Oki T, Yamamoto S, Nagata Y. Body fat distribution in women with polycystic ovary syndrome. Obstet Gynecol 1995; 86: 516-19.
4. Dahlgren E, Johansson S, Lindstedt G, Knutsson F, Oden A, Janson PO et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril 1992; 57: 505-13.
5. Lobo RA, Gysler M, March CM, Goebelsmann U, Mischell DR. Clinical and laboratory predictors of clomiphene response. Fertil Steril 1982; 37: 168-74.
6. Murakawa H, Hasegawa I, Kurabayashi T, Tanaka K. Polycystic ovary syndrome. Insulin resistance and ovulatory responses to clomiphene citrate. Fertil Steril 1999; 44: 23-7.
7. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effect of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998; 25: 1876-80.
8. Mitwally MF, Kuscu NK, Yalcinkaya TM. High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome. Hum Reprod 1999; 14: 2700-3.
9. Yeh HC, Futterweit W, Thornton JC. Polycystic ovarian disease. US features in 104 patients. Radiology 1987; 163: 111-16.
10. Taymor ML. The use and misuse of ovulation-inducing drugs. Infertil Reprod Med Clin North Am 1990; 1: 165-86.
11. Vandermollen DT, Ratts VS, Evans WS, Stovall DW, Kauma SW, Nestler JE. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 2001; 75: 310-15.
12. Nestler JE, Stovall D, Akhter N, Iuorno MJ, Jakubowicz D. Strategies for the use of insulin-sensitizing drug to treat infertility in women with polycystic ovary syndrome. Fertil Steril 2002; 77: 209-15.
13. Kolodziejczyk B, Duleba A, Spacznski RZ, Pawelczyk LP. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 2000; 73: 1149-54.
14. Velazquetz EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994; 43: 647-54.
15. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS. Effect of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82: 524-30.